title: Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.
abstract: OBJECTIVE
  To summarize the epidemiology of pathologic myopia and myopic choroidal neovascularization (CNV) and their impact on vision.
  
  
  METHODS
  Systematic literature review of all English-language studies evaluating the epidemiology and visual burden of pathologic myopia or myopic CNV.
  
  
  METHODS
  PubMed and EMBASE were searched with no time limits using predefined search strings for English-language studies evaluating the epidemiology and visual burden of pathologic myopia and myopic CNV.
  
  
  RESULTS
  In total, 39 relevant publications were identified. Population-based studies reported pathologic myopia to be the first to third most frequent cause of blindness. The prevalence of pathologic myopia was reported to be 0.9%-3.1%, and the prevalence of visual impairment attributable to pathologic myopia ranged from 0.1%-0.5% (European studies) and from 0.2%-1.4% (Asian studies). The prevalence of CNV in individuals with pathologic myopia was reported to be 5.2%-11.3%, and was bilateral in approximately 15% of patients. All studies of visual outcome in patients with myopic CNV (duration ranging from less than 3 months to 21.5 years) reported deterioration in best-corrected visual acuity over time. Older age, subfoveal CNV location, and larger baseline lesion size were predictors of worse visual outcomes.
  
  
  CONCLUSIONS
  Pathologic myopia is an important cause of vision loss worldwide, affecting up to 3% of the population. Of these, a substantial proportion of patients develop myopic CNV, which mostly causes a significant progressive decrease in visual acuity. This condition should therefore be a target for new treatment strategies.
authors.affiliation: Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore. Electronic address: ophwty@nus.edu.sg.
authors.forename: Tien Y
authors.initials: TY
authors.lastname: Wong
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Alberto
authors.initials: A
authors.lastname: Ferreira
authors.affiliation: Value Demonstration Practice, Oxford PharmaGenesis Ltd, Oxford, United Kingdom.
authors.forename: Rowena
authors.initials: R
authors.lastname: Hughes
authors.affiliation: Value Demonstration Practice, Oxford PharmaGenesis Ltd, Oxford, United Kingdom.
authors.forename: Gemma
authors.initials: G
authors.lastname: Carter
authors.affiliation: Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia.
authors.forename: Paul
authors.initials: P
authors.lastname: Mitchell
mesh_terms: D020256:Choroidal Neovascularization / Q000453:epidemiology*; D019317:Evidence-Based Medicine; D006801:Humans; D047728:Myopia, Degenerative / Q000453:epidemiology*; D015995:Prevalence; D014786:Vision Disorders / Q000453:epidemiology*; D014792:Visual Acuity; D019987:Persons with Visual Disabilities / Q000706:statistics & numerical data*